{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"To evaluate the safety of the infusion of inducible caspase 9 (BPZ-1001) modified T-cells followed by dimerizer drug, AP1903. Safety evaluated by number of participants with Adverse events.","groups":[{"description":"Participants who did not move forward to DLI","id":"OG000","title":"Transplant Only"},{"description":"Proceeded to DLI per protocol","id":"OG001","title":"Transplat Plus DLI"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participant who received Donor Lymphocyte infusion and AP 1903","reportingStatus":"POSTED","timeFrame":"up to 3.5 years","title":"To Evaluate the Safety of Donor Lymphocyte Infusion Followed by Dimerizer Drug, AP1903 by Number of Participants With Adverse Events.","type":"PRIMARY","unitOfMeasure":"Participants"}